HBIO 8-K: SEC filing
Harvard Bioscience, Inc.
Filed with the SEC on · accession 0001171843-26-007308
HBIO filed a 8-K (current report) with the SEC on Nov 10, 2026. Harvard Bioscience, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2026, and details of a related conference call.
Summary of the filing
Harvard Bioscience, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2026, and details of a related conference call. The filing is an 8-K under Item 2.02 (Results of Operations and Financial Condition).
Key details
✦ Ask GOAX AI about this filing — what it means for HBIO, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for HBIO?
Click hereFrequently asked questions
What did HBIO file with the SEC on Nov 10, 2026?
HBIO filed a 8-K (SEC filing). Harvard Bioscience, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2026, and details of a related conference call. The filing is an 8-K under Item 2.02 (Results of Operations and Financial Condition).
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other HBIO SEC filings
Get alerts when HBIO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days